Smith Jason Drew's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Feb 11, 2026
- Accession no.
- 0001437749-26-003778
- Filed
- Feb 11, 2026
- Trade date
- Jan 31-Feb 3, 2026
- Filing delay
- 11 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $147.3K. It was filed 11 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith Jason DrewCIK 0001821479 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | Ordinary Shares | MOption exerciseAcquired | +5,500 | –F1 | – | 55,472 | Direct | |
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −2,654 | $19.69 | −$52,257.26 | 52,934 | Direct | |
| Jan 31, 2026 | Ordinary Shares | MOption exerciseAcquired | +3,333 | –F1 | – | 58,805 | Direct | |
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −1,608 | $19.69 | −$31,661.52 | 51,326 | Direct | |
| Jan 31, 2026 | Ordinary Shares | MOption exerciseAcquired | +6,667 | –F1 | – | 49,972 | Direct | |
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −3,217 | $19.69 | −$63,342.73 | 55,588 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | Ordinary Shares | MOption exerciseDisposed | −5,500 | $0.00 | $0 | 5,500 | Direct | |
| Jan 31, 2026 | Ordinary Shares | MOption exerciseDisposed | −3,333 | $0.00 | $0 | 6,667 | Direct | |
| Jan 31, 2026 | Ordinary Shares | MOption exerciseDisposed | −6,667 | $0.00 | $0 | 0 | Direct | |
| Jan 31, 2026 | Ordinary Shares | AGrant or awardAcquired | +32,609 | $0.00 | $0 | 32,609 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Referenced by the price of 3 transactions in Table I.